Oct 18 2012
Protea Biosciences, a leading developer of products and services for biomolecular analysis, announced today at the 2012 AAPS (American Association of Pharmaceutical Scientists) Annual Meeting, the opening of a dedicated Mass Spectrometry Imaging Center (MSIC).
Located in Morgantown, WV, the MSIC offers access to the most advanced biomolecular imaging capabilities, including ultra high resolution mass spectrometry coupled with Protea's revolutionary LAESI® platform.
"Mass Spectrometry coupled with imaging capabilities brings biology to a new level of investigation, providing relevant information on the distribution of specific molecules in a tissue," said Alessandro Baldi PhD, Protea's Vice President and General Manager. "The Center has been designed to support customers who require imaging projects, such as drug/ target interaction studies or analysis of the biodynamics of a living population of cells or colonies. This is entirely new science, that we now make available to the global community of biochemists and biologists."
This year Protea introduced a new imaging device known as LAESI DP-1000, that has been recognized as one of the most innovative products of the year, having received both the Frost & Sullivan New Product Innovation Award for Bioanalytics North America, and R&D Magazine's 2012 "R&D 100 Award."
"The MSIC will provide customers and researchers from around the world access to several imaging technologies including our LAESI DP-1000 system, and soon, a new configuration designed for single cell resolution," continued Dr. Baldi. "We are also ready to host customers looking for demonstration of our LAESI product portfolio as well as training. Our Center is positioned to become a worldwide reference for Mass Spectrometry Biomolecular Imaging, a fast growing segment in the bioanalytical market."
Source: https://proteabio.com